A Study of Vatiquinone for the Treatment of Participants With Friedreich Ataxia
Completed · Phase 2 · NCT05485987
Conditions: Friedreich Ataxia
At a glance
- Research payments reported, 2025
- $8,769
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 5
About the trial
- Sponsor
- PTC Therapeutics
- Tested
- Vatiquinone (drug)
- Dates
- Started 2022-10-12; completion 2024-08-29
- Results posted
- Not yet
The primary objective of the study is to assess the pharmacokinetics (PK) and safety of vatiquinone administered in participants with Friedreich ataxia (FA) younger than 7 years.
From ClinicalTrials.gov, last updated 2025-08-22. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Ptc Therapeutics, Inc. reported $8,769 in research payments for this study in 2025 (1 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.